Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) – B. Riley issued their FY2017 earnings per share (EPS) estimates for Tetraphase Pharmaceuticals in a note issued to investors on Monday. B. Riley analyst M. Kumar forecasts that the biopharmaceutical company will post earnings per share of ($2.70) for the year. B. Riley has a “Buy” rating and a $11.00 price objective on the stock. B. Riley also issued estimates for Tetraphase Pharmaceuticals’ FY2018 earnings at ($2.01) EPS.
Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Tuesday, February 6th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 12th. BidaskClub downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Finally, ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.46.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in Tetraphase Pharmaceuticals during the third quarter worth approximately $107,000. Brighton Jones LLC acquired a new position in Tetraphase Pharmaceuticals during the third quarter worth approximately $108,000. Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in Tetraphase Pharmaceuticals during the second quarter worth approximately $147,000. Finally, Ameriprise Financial Inc. acquired a new position in Tetraphase Pharmaceuticals during the second quarter worth approximately $162,000. 58.28% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director L Patrick Gage acquired 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the purchase, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.